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CeOBJECTIVES The purpose of this study was to assess the diagnostic accuracy of the instantaneous wave-free ratio (iFR)
to characterize, outside of a pre-speciﬁed range of values, stenosis severity, as deﬁned by fractional ﬂow reserve
(FFR) #0.80, in a prospective, independent, controlled, core laboratory–based environment.
BACKGROUND Studies with methodological heterogeneity have reported some discrepancies in the classiﬁcation
agreement between iFR and FFR. The ADVISE II (ADenosine Vasodilator Independent Stenosis Evaluation II) study was
designed to overcome limitations of previous iFR versus FFR comparisons.
METHODS A total of 919 intermediate coronary stenoses were investigated during baseline and hyperemia. From these,
690 pressure recordings (n ¼ 598 patients) met core laboratory physiology criteria and are included in this report.
RESULTS The pre-speciﬁed iFR cut-off of 0.89 was optimal for the study and correctly classiﬁed 82.5% of the stenoses,
with a sensitivity of 73.0% and speciﬁcity of 87.8% (C statistic: 0.90 [95% conﬁdence interval (CI): 0.88 to 0.92,
p < 0.001]). The proportion of stenoses properly classiﬁed by iFR outside of the pre-speciﬁed treatment (#0.85) and
deferral ($0.94) values was 91.6% (95% CI: 88.8% to 93.9%). When combined with FFR use within these cut-offs, the
percent of stenoses properly classiﬁed by such a pre-speciﬁed hybrid iFR-FFR approach was 94.2% (95% CI: 92.2% to
95.8%). The hybrid iFR-FFR approach obviated vasodilators from 65.1% (95% CI: 61.1% to 68.9%) of patients and
69.1% (95% CI: 65.5% to 72.6%) of stenoses.
CONCLUSIONS The ADVISE II study supports, on the basis rigorous methodology, the diagnostic value of iFR in
establishing the functional signiﬁcance of coronary stenoses, and highlights its complementariness with FFR when used
in a hybrid iFR-FFR approach. (ADenosine Vasodilator Independent Stenosis Evaluation II–ADVISE II; NCT01740895)
(J Am Coll Cardiol Intv 2015;8:824–33) © 2015 by the American College of Cardiology Foundation.m the *Cardiovascular Institute, Hospital Clinico San Carlos and Centro Nacional de Investigaciónes Cardiovasculares Carlos III
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na; #Cardiovascular Division of the University of Minnesota, Minneapolis, Minnesota; **St. Anthony’s Heart and Vascular
nter and Colorado Heart and Vascular PC, Denver, Colorado; yyDivision of Cardiology, Department of Medicine, Washington
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AB BR E V I A T I O N S
AND ACRONYM S
ECG = electrocardiogram
FFR = fractional ﬂow reserve
iFR = instantaneous wave-free
ratio
Pa = aortic pressure
PCI = percutaneous coronary
intervention
Pd = distal pressure
Pd/Pa = baseline distal-to-
aortic pressure ratio
ROC = receiver-operating
characteristic
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825T he instantaneous wave-free ratio (iFR)is a recently-introduced pressure-derived,hyperemia-free index for the functional
assessment of coronary stenoses (1). Previous
studies have investigated the classiﬁcation agree-
ment between iFR and fractional ﬂow reserve
(FFR), used as a reference standard, which in gen-
eral has been good (1–8). However, some discrep-
ancies in their agreement have been observed,
potentially related to methodological heterogeneity.
Although the possible beneﬁts and limitations of
nonhyperemic indexes to guide coronary revascular-
ization still need to be determined (9), a prospective
study with rigorous methodology was deemed
required to accurately establish the diagnostic value
of iFR.
Since the introduction of iFR, a hybrid iFR-
FFR diagnostic strategy has been proposed, where
upper and lower iFR cut-offs are used to restrict
decisions on the basis of iFR to those regions in
which its agreement with FFR is very high, and
FFR use is limited to the intermediate iFR range
of values called the “adenosine zone” (3). Hence,
the ADVISE II (ADenosine Vasodilator Indepen-
dent Stenosis Evaluation II) study was designed
to investigate, in a prospective, controlled, core
laboratory–based environment, the diagnostic accu-
racy of iFR to characterize coronary stenosis
severity as determined by FFR, exploring also the
usefulness and convenience of the hybrid iFR-FFR
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ACQUISITION. Patients eligible for enrollment were
age 18 to 85 years, suitable for coronary angiography
and percutaneous coronary intervention (PCI), and
had coronary stenosis (>40% diameter stenosis by
visual assessment) in 1 or more native major epicar-
dial vessel or its branches. Stable angina or acute
coronary syndromes (only nonculprit vessels and
>48 h from symptoms onset in case of myocardial
infarction) were allowed. Complete inclusion and
exclusion criteria are provided in the Online
Appendix. Data acquisition included electrocardio-
graphic (ECG) signal recording (required by the
iFR calculation algorithm) and setting the reading
of mean aortic pressure (Pa) at 3 beats. After
FIGURE 1 Example of the Methodology for Pressure and Electrocardiogram Acquisition
Example of the methodology for pressure traces acquisition in the ADVISE II study. First, correct normalization was recorded (in this case, in the label fractional ﬂow
reserve [FFR] ¼ 0.99). Then, a single electrocardiogram and pressure recording included baseline pressures for a minimum of 20 s, adenosine infusion for a minimum of
2 min, and pressure wire pullback maneuver. Three bookmarks for core laboratory analyses were placed: 1) when adenosine infusion started; 2) when the pullback
maneuver started; and 3) when the pressure sensor reached the tip of the guiding catheter. The operator was blinded to instantaneous wave-free ratio (iFR), which was
calculated off-line at the core laboratory. IV ¼ intravenous; Pa ¼ aortic pressure; Pd ¼ distal pressure; Pd/Pa ¼ baseline distal-to-aortic pressure ratio.
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826intracoronary nitrates (300 mg) and acquisition of
coronary angiograms, Pa and intracoronary distal
pressure (Pd) were recorded as follows (Figure 1).
First, the pressure wire was zeroed and equalized,
and its correct equalization (Pd/Pa ratio of 1.0  0.02)
conﬁrmed during a 10 s acquisition. Afterward, the
pressure sensor was positioned distal to the index
stenosis and the guiding catheter was ﬂushed with
saline. Baseline pressures were recorded for at least
20 s before inducing hyperemia. Adenosine adminis-
tration through a large vein at a rate of 140 mg/kg/min
for a minimum of 2 min and pressure wire pullback
maneuver to check for pressure drift were both
mandatory. In the same pressure recording, 3 book-
marks for core laboratory analyses were placed: 1)
when adenosine infusion started; 2) when the pull-
back maneuver started; and 3) when the pressure
sensor reached the tip of the guiding catheter. If a Pd/
Pa ratio <0.98 or >1.02 at the catheter tip was docu-
mented, the protocol mandated repeat assessment.
The s5/s5i console and PrimeWire Prestige PLUS cor-
onary pressure wire (Volcano Corporation, San Diego,
California) were used in all cases.iFR AND FFR CALCULATION. All pressure recordings
were analyzed by an independent Core Laboratory
(Cardialysis, Rotterdam, the Netherlands) using iFR
calculation software (HARVEST, Volcano Corpo-
ration) fully consistent with online commercial sys-
tems. This computational algorithm performs
automated analyses on the basis of a synchronized
ECG signal and determines the appropriate diastolic
intervals for pressure measurements. By automatic
identiﬁcation of ﬁducial time points in the cardiac
cycle, the diastolic window for pressure measurement
is calculated beginning 25% into diastole and ending
5 ms before end diastole. iFR is then calculated as
Pd/Pa ratio during this pre-speciﬁed period of time,
within mid to late diastole under nonhyperemic
conditions—the wave-free period—when it has been
shown that intrabeat microvascular resistance is sta-
ble and minimized (1,6,10).
FFR was experimentally and clinically validated
under conditions of maximum and stable hyperemia
(11) and is automatically calculated by current
computational software as the minimum Pd/Pa ratio
found in the pressure recording. However, during
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827intravenous adenosine infusion, the minimum hy-
peremic Pd/Pa ratio might develop before stabilization
of hyperemia, a situation that ﬂaws the theoretical
framework of FFR, as neither driving nor distal pres-
sures are stable (12). Hence, conforming to its original
validation (11,13), core laboratory analyses included a
thorough review of pressure recordings to corroborate
that FFRwas calculated: 1) after initiation of adenosine
infusion; 2) within stable hyperemia; and 3) before the
pullback maneuver. Stable hyperemia was deﬁned as
the plateau in mean Pa after stabilization of changing
hemodynamics following the initiation of adenosine
infusion and before the pullback maneuver (12). If a
plateau was not clearly observed, stable hyperemia
was then deﬁned as the period of pressure recording in
which no further systematic fall in Pa was observed,
following the initiation of adenosine infusion but
before the initiation of the pullback (12). Within stable
hyperemia, the minimum Pd/Pa ratio was then labeled
as FFR.
Core laboratory analyses included an exhaustive
evaluation of pressure waveforms to conﬁrm that
none of the following exclusion criteria were present:
inappropriate normalization of the pressure wire
(Pd/Pa ratio <0.98 or >1.02), ECG artifacts or signiﬁ-
cant arrhythmias in the ﬁrst 20 s of the recording
(“iFR calculation window”), loss of Pa or Pd signals at
any point during the recording, automatic calculation
pitfalls (identiﬁcation of FFR during ectopic beats, Pa
or Pd noise, wire whipping artifacts, and so on),
dampening of Pa or Pd waveforms, pressure drift
higher than <0.98 or >1.02, and absence of ECG or
pressure-pullback recording.
HYBRID iFR-FFR APPROACH. This hybrid iFR-FFR
diagnostic strategy was designed to increase adop-
tion of physiology-guided PCI by decreasing the need
for vasodilators whereas maintaining a very high
classiﬁcation agreement with a lone-FFR strategy (3).
Two independent iFR values with very high negative
and positive predictive values to exclude (defer-iFR
value) and identify (treatment-iFR value) FFR-
signiﬁcant stenoses were investigated, assuming thus
that only those stenoses with iFR values in-between
would require vasodilator drugs for standard FFR
classiﬁcation. On the grounds of retrospectively-
acquired data, it was found that a treatment iFR
value #0.85, a deferral iFR value $0.94, and the use
of FFRwithin the 0.86 and 0.93 iFR values (“adenosine
zone”) resulted in an overall 95% classiﬁcation agree-
ment with a lone-FFR strategy and obviated the need
for vasodilators in 57% of patients.
ENDPOINTS. The primary endpoint of the study was
the percentage of stenoses properly classiﬁed by theiFR values #0.85 and $0.94, as proposed by the
hybrid iFR-FFR approach. Hemodynamic severity
was deﬁned as FFR #0.80. Pre-speciﬁed secondary
endpoints were: 1) the diagnostic performance of the
iFR 0.89 cut-off; 2) the optimal iFR cut-off against
FFR #0.80 derived from receiver-operating charac-
teristic (ROC) curve analyses; 3) the minimum iFR
exclusion ranges around the iFR 0.89 cut-off in which
the iFR and FFR agreement was $80%, $90%, and
$95%; 4) the correlation coefﬁcient between iFR and
FFR; and 5) the proportion of stenosis and patients
free from vasodilator drugs expected from the
previously-mentioned pre-speciﬁed hybrid iFR-FFR
approach.
STATISTICAL ANALYSIS. For quantitative variables,
data are expressed as mean  SD. Non-normal data are
reported as the median with ﬁrst and third quartiles
(Q1, Q3). For categorical data, counts and percentages
are provided. The 95% conﬁdence intervals (CIs) of
the means of continuous variables and percentages of
categorical variables were calculated with t tests and
Clopper-Pearson (Exact) approaches, respectively.
ROC curve analyses were performed to determine the
optimal iFR cut-off against FFR #0.80, deﬁned as the
value that maximized correct classiﬁcation. Pearson’s
correlation coefﬁcient (r) between iFR and FFR was
computed, and the Fisher Z transformation was used
to provide its 95% CIs. Linear regression was used to
further characterize the iFR and FFR relationship, and
being as this was a multicenter study, between–center
variability was assessed by adding participating cen-
ter as random effect. However, a signiﬁcant effect
parameter was not found for any of the centers, and
the total effect of adding such a center effect to the
analysis was nonsigniﬁcant (p ¼ 0.165). We, therefore,
concluded that the center effect could be ignored. The
SAS version 9.2 (SAS Institute Inc., Cary, North Car-
olina) and STATA 12.1 (StataCorp, College Station,
Texas) statistical software packages were used.
Applicable tests were 2-tailed, and differences were
considered signiﬁcant at p < 0.05.RESULTS
STUDY POPULATION. Between January 9, 2013, and
June 28, 2013, 919 stenoses from 797 patients were
investigated and included in the study. Of these ste-
noses, 229 (24.9%) met at least 1 of the pre-deﬁned
core laboratory exclusion criteria, leaving 690 steno-
ses from 598 patients for ﬁnal analyses. A STARD-
type (STAndards for the Reporting of Diagnostic
Accuracy Studies) (14) ﬂow chart depicting this pro-
cess is provided in Figure 2. Clinical and angiographic
FIGURE 2 Process Followed by Eligible Stenosis
A STARD-type ﬂow diagram showing the process followed by eligible stenosis from inclusion to ﬁnal results. ECG ¼ electrocardiogram; other
abbreviations as in Figure 1.
TABLE 1 General Characteristics of the Study Population
(n ¼ 598)
Mean  SD or % 95% CI*
Baseline demographics
Age (yrs) 63.6  10.8 62.7–64.5
Male 68.9 65.0–72.6
Medical history
Prior myocardial infarction 35.2 31.3–39.2
Prior PCI 49.1 45.0–53.2
Prior CABG 4.7 3.2–6.7
Congestive heart failure 8.4 6.3–11.0
Hypertension 78.8 75.3–82.1
Diabetes mellitus 35.0 31.1–39.0
Current smoker (#6 months) 22.6 19.3–26.3
History of other vascular disease 17.4 14.4–20.8
Renal dysfunction
(serum creatinine >2.0)
2.9 1.7–4.6
Pulmonary disease 12.0 9.5–14.9
Clinical presentation
Stable angina 53.5 49.4–57.6
Unstable angina 25.3 21.8–28.9
Silent ischemia 13.1 10.5–16.1
NSTEMI (>48 h before enrollment) 5.6 3.9–7.7
STEMI (>48 h before enrollment) 2.5 1.4–4.1
*95% conﬁdence intervals (CIs) of the mean.
CABG ¼ coronary artery bypass graft; NSTEMI ¼ non–ST-segment elevation
myocardial infarction; PCI ¼ percutaneous coronary intervention; STEMI ¼
ST-segment elevation myocardial infarction.
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828characteristics of the study population are shown in
Tables 1 and 2. Overall, mean age was 63.6  10.8
years, and 68.9% were male patients. The most
common clinical presentation was chronic stable
angina (53.5%), followed by unstable angina (25.3%),
and the left anterior descending artery was the most
commonly interrogated vessel (54.5%). Figure 3
shows the distribution of the FFR values in theTABLE 2 General Characteristics of Epicardial Stenosis Included
in Study (n ¼ 690)
% or Mean  SD 95% CI*
Vessel
Left anterior descending artery 54.5 50.7–58.3
Left circumﬂex 25.7 22.4–29.1
Right coronary artery 19.9 16.9–23.0
Stenosis characteristics†
Lesion length (mm) 14.0  7.9 13.40–14.59
Reference vessel diameter (mm) 3.0  0.50 2.93–3.01
Percentage of diameter stenosis 60.0  13.0 58.7–60.7
Lesion type (AHA)
A 34.9 31.3–38.6
B1/B2 52.2 48.4–56.0
C 12.9 10.4–15.6
Current in-stent restenosis 7.1 5.3–9.3
*95% conﬁdence intervals (CIs) of the mean. †Visual assessment.
AHA ¼ American Heart Association.
FIGURE 3 Distribution of the FFR Values Observed in the Study
Frequency histogram with superimposed normal distribution
of the fractional ﬂow reserve (FFR) values in study population.
Please note the unimodal FFR distribution as well as data
clustering around the FFR 0.80 cut-off point.
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829study. In general, the study population was
composed of stenoses of intermediate angiographic
(diameter stenosis: 60  13% by visual assessment)
and physiological severity (FFR: mean 0.83  0.11;FIGURE 4 iFR Versus FFR Relationship
FF
R
iFR
FFR=0.782*iFR+0.121
R2=0.65, p<0.001
A B
(A) The scatterplot of the relationship between iFR and FFR. Vertical line
0.86 and 0.93). The horizontal line is placed at the clinically-adopted 0
of iFR against FFR#0.80. The optimal iFR cut-off identiﬁed in the ADVIS
Figure 1.median 0.84 [Q1 0.77, Q3 0.90]). Finally, 248 (35.9%)
vessels had FFR #0.80.
DIAGNOSTIC ACCURACY OF iFR AGAINST FFR.
Figure 4A shows the scatterplot of the relationship
between iFR and FFR. There was a strong linear cor-
relation between both indexes (r ¼ 0.81, 95% CI: 0.78
to 0.83, p < 0.001). ROC analyses identiﬁed 0.89 as
the optimal iFR cut-off, with an area under the ROC
curve (C statistic) of 0.90 (95% CI: 0.88 to 0.92,
p < 0.001) (Figure 4B). Notably, the optimal iFR cut-
off observed in the study matched the pre-speciﬁed
one. This 0.89 iFR cut-off correctly classiﬁed 82.5%
of total stenoses, with a sensitivity of 73.0% and
speciﬁcity of 87.8%. For the study prevalence
(FFR #0.80, 35.9%), the positive predictive and
negative predictive values of this cut-off were 77.0%
and 85.3%, respectively.
STUDY ENDPOINTS. The iFR treatment (#0.85) and
deferral ($0.94) values correctly classiﬁed 88.1%
(95% CI: 81.6% to 92.9%) and 93.1% (95% CI: 89.8% to
95.6%) of the stenoses, respectively. Thus, the overall
proportion of stenoses properly classiﬁed by iFR
outside such pre-speciﬁed iFR treatment (#0.85)
and deferral ($0.94) values was 91.6% (95% CI:
88.8% to 93.9%) (Figure 5). The best iFR exclusion
range around the pre-speciﬁed 0.89 cut-off to
achieve $80% diagnostic accuracy was this cut-offSe
ns
iƟ
vi
ty
1-Specificity
Area under the curve:
0.90 (95% CI: 0.88 to 0.92), p<0.001
s are placed at the boundaries of the “adenosine zone” (iFR values of
.80 FFR cut-off value. (B) The receiver-operating characteristic curve
E II study was 0.89. CI ¼ conﬁdence interval; other abbreviations as in
FIGURE 5 Primary Endpoint of the Study and Hybrid
iFR-FFR Approach
The iFR treatment (#0.85) and deferral ($0.94) values correctly
classiﬁed 88.1% and 93.1% of investigated stenoses, respectively.
Theoverall proportionof stenosesproperly classiﬁedby iFRoutside
of the pre-speciﬁed iFR values was 91.6%. This value increased to
94.2% after including standard classiﬁcation with FFR in-between
(hybrid iFR-FFR approach). Abbreviations as in Figure 1.
FIGURE 6 Absolute Counts of Stenoses Across Categories of
iFR and FFR
Please note how most of the between-indexes disagreement
was located within the FFR “gray zone” (FFR values between
0.75 and 0.80), where the ischemic potential of the interro-
gated stenosis is known to be less certain. Abbreviations as
in Figure 1.
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830itself, because it correctly classiﬁed 82.5% of total
stenoses. To achieve 90% and 95% classiﬁcation
agreement with FFR, the minimum iFR exclusion
ranges below and above the optimal 0.89 cut-off
were #0.86 (to predict FFR #0.80) and $0.94 (to pre-
dict FFR >0.80), which provided a percentage agree-
ment of 91.0%, and #0.78 (to predict FFR #0.80)
and $0.95 (to predict FFR >0.80), which provided a
percent agreement of 95.3%. Finally, Figure 6 demon-
strates how most of the classiﬁcation disagreement
between iFR and FFRwas located within the FFR “gray
zone” (FFR values between 0.75 and 0.80), where the
ischemic potential of the stenosis is known to be less
certain (15).
HYBRID iFR-FFR APPROACH. The percentage of ste-
noses properly classiﬁed by the pre-speciﬁed hybrid
iFR-FFR approach was 94.2% (95% CI: 92.2% to
95.8%), and it had associated sensitivity, speciﬁcity,
and positive and negative predictive values of 90.7%,
96.2%, 93.0%, and 94.9%, respectively (Figure 5). The
estimated proportion of patients and stenoses free
from vasodilator agents by such a pre-speciﬁed
hybrid iFR-FFR approach amounted to 65.1% (95%
CI: 61.1% to 68.9%) and 69.1% (95% CI: 65.5% to
72.6%), respectively.
DISCUSSION
The results of the ADVISE II study support the diag-
nostic value of iFR in establishing the hemodynamicseverity of coronary stenoses and highlight its
complementariness with FFR when used in a hybrid
iFR-FFR approach.
iFR AS AN ALTERNATIVE FOR PHYSIOLOGICAL
ASSESSMENT OF CORONARY STENOSIS. Although
decision-making on the basis of intracoronary physi-
ology was initiated 20 years ago with Doppler-tipped
guide wires (15), the demonstration that intra-
coronary physiology is not only safe, but also results
in better patient outcomes, came from studies
comparing FFR with coronary angiography (16,17).
This clinical evidence has made FFR the technique of
choice for physiological assessment of coronary ste-
noses (18). Hence, the introduction of iFR took place
at a time in which FFR constituted the paradigm (and
for many the synonym) of intracoronary physiology,
which was concomitantly facilitated by many com-
mon aspects between the 2 techniques. iFR is derived
from the same theoretical framework as FFR (i.e., the
relationship between the translesional pressure ratio
and the impairment in myocardial blood supply
caused by the interrogated stenosis) and is obtained
with conventional pressure wires and appropriate
software (1,11). Without a doubt, the main attrac-
tiveness of iFR is the avoidance of vasodilator drugs,
identiﬁed as a cumbersome requirement for FFR
interrogation (19). Thus, iFR appeared to many to be a
potential step ahead toward the simpliﬁcation of
physiological stenosis assessment introduced by FFR
many years ago.
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831The publication of the ﬁrst study on iFR generated
signiﬁcant interest among interventional cardiologists
(1–8). The RESOLVE (Multicenter Core Laboratory
Comparison of the Instantaneous Wave-free Ratio and
Resting Pd/Pa with Fractional Flow Reserve) study (8),
a recent pooled-retrospective analysis, provides an
excellent perspective of published and unpublished
iFR versus FFR comparisons performedwithin the ﬁrst
year after the publication of the ADVISE study (1). In
RESOLVE, data from individual studies was rean-
alyzed after standardization and application of inclu-
sion and exclusion criteria, and iFR was recalculated
using the original iFR calculation algorithm. There was
relatively little variation in the diagnostic accuracy of
iFR among the 6 independent research groups (n ¼
1,593), and it was proposed that these differences
probably resulted from inconsistencies in data collec-
tion and analysis inherently linked to the retrospective
design—including nonuniform patient and lesions
characteristics, varying acquisition equipment and
protocols, absence of ECG and ﬁnal pressure wire
pullback to exclude pressure drift, among others—as
highlighted by the investigators.
The ADVISE II study was designed to address the
limitations of retrospective studies like RESOLVE
through a prospective, multicenter design, with
rigorous, standardized methodology and indepen-
dent analysis at a core laboratory. Key differential
aspects included FFR technique standardization,
corroboration of appropriate pre-measurement
equalization, the acquisition of a single ECG and
pressure recording encompassing baseline, induction
and achievement of hyperemia, pressure wire pull-
back, and persistence of calibration at the catheter
tip. This rigorous methodology becomes highlighted
by the high exclusion rate (nearly 25% of tracings) in
ADVISE II, superior to that reported in RESOLVE
(17%), which is probably explained by the fact that in
RESOLVE, exclusions due to ECG were not consid-
ered. In our study, nearly one-half (48%) of the
excluded traces resulted from ECG pitfalls, probably
mirroring a lack of awareness by catheterization lab-
oratory personnel on the relevance of ECG for accu-
rate iFR calculation and indicating an important
methodological difference with RESOLVE. Impor-
tantly, in consonance with FFR theoretical framework
(11), ADVISE II mandated FFR calculation as the
minimal Pd/Pa ratio during the steady-state hyper-
emic plateau. Finally, a higher C statistic (0.90) in
ADVISE II than in RESOLVE (0.81) was documented,
and a very similar optimal iFR cut-off value was
found (0.89 in ADVISE II, 0.90 in RESOLVE). This
provides further evidence on the appropriateness of
the use of this cut-off value in future studies.Finally, RESOLVE also reported a good diagnostic
performance of the largely neglected baseline Pd/Pa
ratio. As the interest in the diagnostic performance of
baseline Pd/Pa emerged when ADVISE II was already
initiated, baseline Pd/Pa analyses were not included
as pre-speciﬁed endpoints of the study. Yet, to
investigate the value of this nonhyperemic index, a
post-hoc analysis of ADVISE II data with the same
methodology applied to the iFR versus FFR compar-
ison reported in this paper has been performed, and is
discussed in detail elsewhere (20).
USE OF THE HYBRID iFR-FFR APPROACH. The sim-
plest way of assessing the diagnostic accuracy of iFR
is to use FFR dichotomized at 0.80 as the reference
standard. However, this approach is fraught by the
limitations of dichotomizations in biological contin-
uous systems (2,3,21). This makes comparisons sen-
sitive to the characteristics of coronary stenosis
populations, where lower intertechnique and intra-
technique agreements are, by deﬁnition, expected
when used in unimodal distributions peaking around
cut-offs, as compared with broader distributions
where more very severe and minimal stenoses are
present (21). In this regard, it is important to
acknowledge that the distribution of FFR values in
ADVISE II was intermediate (diameter stenosis:
60  13%; FFR: 0.83  0.1) (Figure 3), which is the
most challenging for the purpose of establishing
the diagnostic accuracy of iFR, as data clustering near
the FFR cut-off helps small differences lead to clas-
siﬁcation disagreement (2,3,21).
To overcome these limitations, a hybrid iFR-FFR
approach has been proposed as a way to translate
into practice the potential value of iFR as a diagnostic
tool. The ADVISE II study supports the diagnostic
value of this hybrid iFR-FFR diagnostic approach, as
it properly classiﬁed 94.2% of total stenosis, with
values of speciﬁcity, sensitivity, and positive and
negative predictive values >90%. With this strategy,
adenosine would not be required in 69% of the ste-
noses, and in 65% of patients, adenosine would not
be needed at all. These ﬁgures support the potential
of iFR to ease catheterization laboratory workﬂow
and to reduce costs associated with ischemia-driven
revascularization.
IMPLICATIONS OF ADVISE II RESULTS FOR CLINICAL
PRACTICE. The ADVISE II study probably constitutes
the deﬁnitive direct comparison between iFR and FFR.
Because the low adoption of FFR (22) is clearly the ﬁrst
obstacle for translating the beneﬁts of ischemia-driven
revascularization to patients, the results of ADVISE II
may contribute to increase its implementation, parti-
cularly when used synergistically with FFR. This is an
PERSPECTIVES
WHAT IS KNOWN? iFR is a novel adenosine-free
index developed to simplify stenosis severity assess-
ment and to expand the use of physiology in the
catheterization laboratory. Although previous studies
suggested a good overall classiﬁcation agreement
between iFR and FFR in terms of functional stenosis
severity, a marked variability was noted between in-
dividual studies. ADVISE II was designed to validate
the accuracy of iFR by applying a rigorous methodol-
ogy that addressed methodological limitations of
previous studies.
WHAT IS NEW? The study identiﬁed that the pre-
speciﬁed hybrid iFR-FFR approach properly classiﬁed
94.2% of the stenoses and obviated vasodilator need
in 69.1% (95% CI: 65.5% to 72.6%) stenoses.
WHAT IS NEXT? Further to using FFR as a reference
technique to assess iFR, as in ADVISE II, future studies
must focus on demonstrating noninferiority of iFR
with respect to FFR in terms of clinical outcomes
when it is used as a decision-making tool.
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832urgent task, because recent studies like RIPCORD
(Does Routine Pressure Wire Assessment Inﬂuence
Management Strategy at Coronary Angiography for
Diagnosis of Chest Pain?) have demonstrated that
revascularization decisions on the basis of angiog-
raphy and available clinical information are modiﬁed
in >30% of cases when physiological interrogation is
performed (23). At a time that FFR is used in a minority
of cases and, therefore, similar rates of misdiagnosis
should be expected in non-FFR practices, a huge net
beneﬁt would be expected if a hybrid iFR-FFR
approach is adopted, even if 5.8% stenoses would not
be properly classiﬁed according to FFR (24).
A second obstacle to translate available evidence
on the beneﬁt of FFR to patients is the restriction of
physiological interrogation to intermediate stenosis,
and not to all potential revascularization targets,
irrespective of their angiographic appearance. It is
important to note that, in randomized studies, FFR
has been measured in all stenoses regardless of their
angiographic severity (16,17,25). However, as high-
lighted by observational studies including ADVISE II,
most interventional cardiologists do not measure FFR
in stenoses judged as clearly severe or nonsevere on
the grounds that it interferes with catheterization
laboratory workﬂow and increases costs. Although
the cost-effectiveness analysis of the FAME (Frac-
tional Flow Reserve Versus Angiography for Multi-
vessel Evaluation) study has clearly demonstrated
that the latter perception is wrong (25), the sharp
decrease in the need for adenosine found in ADVISE II
constitutes a potential solution for the former
obstacle. Indeed, the forthcoming multicenter
SYNTAX II trial (NCT02015832) that applies ischemia-
driven revascularization to patients with triple-vessel
disease treated with PCI has opted for a hybrid iFR-
FFR approach to reduce procedural time in this type
of complex procedure.
STUDY LIMITATIONS. The ADVISE II study is the ﬁrst
prospective, core laboratory–based intracoronary
physiology study. Therefore, being a validation
analysis, stringent core-laboratory criteria were
applied. Although this approach reduces the potential
for bias and threats to statistical internal validity, it
might also limit the generalization of the ﬁndings todifferent populations. However, the fact that the
diagnostic accuracy of iFR observed in clinical retro-
spective registries shows very little variations from
that observed in this meticulous prospective study is
reassuring.
CONCLUSIONS
The ADVISE II study observed a high diagnostic ac-
curacy of iFR as compared to FFR and, therefore,
supports the diagnostic value of this nonhyperemic
index in establishing the hemodynamic severity of
coronary stenoses and highlight its complementari-
ness with FFR when used in a hybrid iFR-FFR
approach.
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